IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.408,20 +280,85 (+0,47%)
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796,95k | N/A | 1968 |
| Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610,23k | N/A | 1964 |
| Dr. Dansu Li Ph.D. | Head of Technology | N/A | N/A | N/A |
| Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | N/A | N/A | 1957 |
| Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | N/A | N/A | 1968 |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | N/A | N/A | N/A |
| Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | N/A | N/A | 1962 |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Chief Medical Officer | N/A | N/A | N/A |
| Ms. Andrea Epstein | Controller | N/A | N/A | N/A |
Descripción
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Gobierno corporativo
El ISS Governance QualityScore de Aprea Therapeutics, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.
